CML Horizons 2018: Learn. Share. Grow.
4 – 6 May 2012, Warsaw, Poland
Welcome
- Welcome The CML Horizons Steering Committee, Jana Pelouchová, Giora Sharf and Euzebiusz Jan Dziwinski – PDF1 PDF2 Video Webstream
- Update on the CML Advocates Network (Jana Pelouchová,) – PDF Video Webstream 1 and Video Webstream 2
- Tribute to Ferdinand Mwangura (Amal Hrim) – PDF Video Webstream
CML 301 – Introduction to CML, science and data Overview of CML Horizons (Šarūnas Narbutas and Jan Geissler) – PDF Video Webstream
Medical Session #1: CML Management in Countries with Access Challenges
- Access to treatment (Eastern Europe) (Andrija Bogdanovic) – PDF Video Webstream
- Access to monitoring (Africa) (Nicholas Anthony Othieno Abinya) – PDF – Video Webstream
- TFR in low and middle-income countries (Asia) (Raymond Wong) – PDF – Video Webstream
Advocacy Session #1: Improving the communication with patients
- Patient-Doctor Communications: Introduction and moderation, Why is patient-doctor communication important (Cristián Neves) PDF
- Roleplay: Gail Sperling(doctor; Gianantonio Rosti (patient)and Erin Schwarz(wife) – Panel discussion with Q&A, – Video Webstream
- Communication with patients; Managing anxiety (Irene Caballes) – PDF – Video Webstream
- Talking to teenage patients (Cristián Neves) – PDF – Video Webstream
- Empowering the caregivers (Gail Sperling – LLS) – PDF – Video Webstream
Regional Sessions Report – Video Webstream
Advocacy Session #2: Evidence-Based Advocacy 1 – Generating the evidence
- Barking up the right tree on access, policy & research. Why evidence-based advocacy? (Jan Geissler) – PDF Video Webstream
- What kind of data? Some advocacy examples Doing surveys: The Leukaemia Care Patient Experience Survey (Zack Pemberton-Whiteley) –PDF – Video Webstream
- Social Media-based data: Facebook Group example (Toni Montserrat) PDF – Video Webstream
- Patient-Reported Outcome Measures (Felice Bombaci) – PDF – Video Webstream
- Doing Focus Groups: Max Foundation Focus Group on PCR (Cathy Scheepers) – PDF – Video Webstream
Medical Session #2: First-line decision making
- Did the introduction of generics change clinical decisions in first-line therapy? (Gianantonio Rosti) – PDF – Video Webstream
- Pediatrics: New labels of Nilotinib and Dasatinib (Meinolf Suttorp) Available from 1st July 2018
- Update on Treatment Guidelines (Delphine Rea) – PDF – Video Webstream
Medical #3: Side Effect Management
- Long-term side effects of TKIs (Gianantonio Rosti) – PDF – Video Webstream
- Collaboration of cardiologists and hematologists (Tristan Mirault + Delphine Rea) – PDF – Video Webstream
- Side effect management: Nurse experience (Irene Caballes) – PDF – Video Webstream
Advocacy #3: Stopping CML treatment – clinical data, bad practice, patient information
- Clinical update on TFR studies (Delphine Rea) – PDF – Video Webstream
- Bad Practice examples (Jan Geissler) – PDF – Video Webstream
- Informing patients about TFR (Giora Sharf) – PDF – Video Webstream
Medical #4: New Agents / New Regimens
- ABL001/Ascitinib trials (Delphine Rea) – PDF – Video Webstream
- Is there any evidence to use lower TKI doses? (Delphine Rea) – PDF – Video Webstream
- How will therapeutic landscape in CML change in next 5 years in your region? Panel discussion with speakers from Asia (Raymond Wong) Africa (Nicholas Anthony Othieno Abinya) Eastern Europe (Andrija Bogdanovic), Europe (Gianantonio Rosti) – PDF – Video Webstream
Advocacy #4: Evidence-based advocacy 2 – Using the evidence (Theory & Examples)
- Influencing industry: Example WECAN Legal Agreements survey (Šarūnas Narbutas) – PDF – Video Webstream
- Influencing regulators and HTA: Example patient evidence in HTA in the UK (Zack Pemberton-Whiteley) – PDF – Video Webstream
- Influencing scientists and clinicians: Example Surveys on adherence, TFR and generics (Jan Geissler) – PDF – Video Webstream
Best Poster Award, closing and farewell; The CML Horizons Steering Committee – Video Webstream